Windlas Biotech Limited
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable an… Read more
Windlas Biotech Limited (WINDLAS) - Total Liabilities
Latest total liabilities as of September 2025: ₹2.80 Billion INR
Based on the latest financial reports, Windlas Biotech Limited (WINDLAS) has total liabilities worth ₹2.80 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Windlas Biotech Limited - Total Liabilities Trend (2018–2025)
This chart illustrates how Windlas Biotech Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Windlas Biotech Limited Competitors by Total Liabilities
The table below lists competitors of Windlas Biotech Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FLITTO Inc
KQ:300080
|
Korea | ₩10.93 Billion |
|
Biosyent Inc.
PINK:BIOYF
|
USA | $7.88 Million |
|
Canyon Resources Ltd
AU:CAY
|
Australia | AU$6.50 Million |
|
Micro Systemation AB Series B
LSE:0FBM
|
UK | Skr115.70 Million |
|
Imagicaaworld Entertainment Limited
NSE:IMAGICAA
|
India | ₹5.48 Billion |
|
ShareHope Medicine Co Ltd
TWO:8403
|
Taiwan | NT$2.75 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Windlas Biotech Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Windlas Biotech Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Windlas Biotech Limited (2018–2025)
The table below shows the annual total liabilities of Windlas Biotech Limited from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹2.55 Billion | +44.48% |
| 2024-03-31 | ₹1.76 Billion | +39.12% |
| 2023-03-31 | ₹1.27 Billion | +31.66% |
| 2022-03-31 | ₹962.33 Million | -0.79% |
| 2021-03-31 | ₹970.04 Million | -24.70% |
| 2020-03-31 | ₹1.29 Billion | +23.17% |
| 2019-03-31 | ₹1.05 Billion | -36.55% |
| 2018-03-31 | ₹1.65 Billion | -- |